PharmaNews.eu
  • Home
  • Business
  • R&D
  • EC
  • EMA
  • Events
  • Open Calls

Novo Nordisk

Novo Nordisk

Novo NordiskNovo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Novo Nordisk RSS Channel

Filters
List of articles in category Novo Nordisk
Title Published Date
Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors 06 March 2019
Abbott and Novo Nordisk enter partnership to provide integrated digital solution to people with diabetes using insulin 20 February 2019
Embark and Novo Nordisk enter collaboration to discover novel therapeutics for obesity and metabolic disease 08 November 2018
Addressing social and cultural drivers of type 2 diabetes is key to its treatment and prevention 02 October 2018
Novo Nordisk announces plans to transform its approach to Research & Development 20 September 2018
Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins 17 August 2018
Kallyope and Novo Nordisk announce collaboration to discover novel therapeutics for obesity and diabetes 19 June 2018
Novo Nordisk increases commitment to stem cell-based therapies 16 May 2018
Novo Nordisk participates in new research project Hypo-RESOLVE to investigate hypoglycaemia and its impact in diabetes 01 May 2018
Red Cross and Novo Nordisk announce ground-breaking partnership to tackle chronic care in humanitarian crises 23 April 2018
Switching to Tresiba® is highly cost-effective and cost-saving in a real-world setting 07 November 2017
More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments 12 September 2017
Call for applications: 2017 Lyfebulb-Novo Nordisk Innovation Summit and Award 07 June 2017
Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests GBP 115m in new research centre 30 January 2017
Novo Nordisk and Glooko partner to develop digital health solutions for people with diabetes 09 January 2017
Novo Nordisk extends programme for children with diabetes in developing countries 14 April 2015
Novo Nordisk and Karolinska Institutet join forces in the field of diabetes 10 February 2015
6,000 new jobs in Novo Nordisk create a further 15,000 jobs in Denmark 11 June 2014
Novo Nordisk invests 550 million Danish kroner in new purification pilot plant in Denmark 13 March 2014
IDegLira demonstrates superior glycaemic control and weight loss with a low rate of hypoglycaemia 03 December 2013

Page 1 of 3

  • Start
  • Prev
  • 1
  • 2
  • 3
  • Next
  • End
  1. You are here:  
  2. Home
  3. Novo Nordisk

About

  • Home
  • Terms and Conditions
  • Contact

Advertise

Top News Channels

  • Business
  • Research
  • EMA
  • Events

Follow us

Didn't we got you connected? If not, please note the following magic buttons:

  • Facebook
  • Twitter
  • RSS 2.0
  • Atom 1.0

Newsletter

Stay updated on the latest Pharma News. Subscribe now, it's free!

Copyright © 2025 PharmaNews.eu. All Rights Reserved.